Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies
Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2020-08, Vol.10 (1), p.14289-14289, Article 14289 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14289 |
|---|---|
| container_issue | 1 |
| container_start_page | 14289 |
| container_title | Scientific reports |
| container_volume | 10 |
| creator | Steeds, Kimberley Hall, Yper Slack, Gillian S. Longet, Stephanie Strecker, Thomas Fehling, Sarah Katharina Wright, Edward Bore, Joseph Akoi Koundouno, Fara Raymond Konde, Mandy Kader Hewson, Roger Hiscox, Julian A. Pollakis, Georgios Carroll, Miles W. |
| description | Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. Serological studies are vital to assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as alternatives to live viruses, which require high levels of bio-containment, in serological and viral entry assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseudotyped virus system, which is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics. Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could be used to provide a better understanding of the putative correlates of protection against EBOV. |
| doi_str_mv | 10.1038/s41598-020-71225-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7459353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2696376902</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-989eb3b6fd2a18f7bcb91f102d27bd7b2e6e952ce21f8d5320fc82c16cdbf9f83</originalsourceid><addsrcrecordid>eNp9kVFrFDEUhQdRbKn9Az5IwBdfRpObmUzyIkiptlBQUPc1TDLJbsrsZM3NtOy_N-PWsgqalyTc7557LqeqXjL6llEu32HDWiVrCrTuGEBbsyfVKdCmrYEDPD16n1TniLe0nBZUw9Tz6oSDFFLy7rTKX9DNQ8z7XZjWJHqy-roi9yFvyKWJY0_uQpqRrMe9jbsUswsTCUhw3rkUYiI5kqvrVc2IXz4bR3pEh7h1U17EJjfn1I8BF_F-ysHEITh8UT3z_Yju_OE-q75_vPx2cVXffP50ffHhprYthVwrqZzhRvgBeiZ9Z6xRzDMKA3Rm6Aw44VQL1gHzcmg5UG8lWCbsYLzykp9V7w-6u9ls3WCLq-JG71LY9mmvYx_0n5UpbPQ63umuaRVveRF48yCQ4o_ZYdbbgNaNYz-5OKOGhisBXDS0oK__Qm_jnKayngahBO-EovA_ikkpQAGVy1g4UDZFxOT8o2VG9ZK-PqSvS_r6V_qalaZXx8s-tvzOugD8AGApTWuXjmb_W_Ynrji8Ng</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1886292083</pqid></control><display><type>article</type><title>Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Steeds, Kimberley ; Hall, Yper ; Slack, Gillian S. ; Longet, Stephanie ; Strecker, Thomas ; Fehling, Sarah Katharina ; Wright, Edward ; Bore, Joseph Akoi ; Koundouno, Fara Raymond ; Konde, Mandy Kader ; Hewson, Roger ; Hiscox, Julian A. ; Pollakis, Georgios ; Carroll, Miles W.</creator><creatorcontrib>Steeds, Kimberley ; Hall, Yper ; Slack, Gillian S. ; Longet, Stephanie ; Strecker, Thomas ; Fehling, Sarah Katharina ; Wright, Edward ; Bore, Joseph Akoi ; Koundouno, Fara Raymond ; Konde, Mandy Kader ; Hewson, Roger ; Hiscox, Julian A. ; Pollakis, Georgios ; Carroll, Miles W.</creatorcontrib><description>Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. Serological studies are vital to assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as alternatives to live viruses, which require high levels of bio-containment, in serological and viral entry assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseudotyped virus system, which is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics. Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could be used to provide a better understanding of the putative correlates of protection against EBOV.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-71225-1</identifier><identifier>PMID: 32868837</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250 ; 631/326/596 ; 692/699 ; Animal models ; Antibodies ; Antibodies, Neutralizing - immunology ; Brain slice preparation ; Capsaicin ; Capsaicin receptors ; Capsazepine ; Cell culture ; Central nervous system ; Containment ; Cyclooxygenase-2 ; Cytokines ; Ebola virus ; Ebolavirus ; Ebolavirus - immunology ; Glycoproteins ; Hippocampus ; HIV ; HIV-1 - immunology ; Human immunodeficiency virus ; Humanities and Social Sciences ; Humans ; Inflammation ; Interleukin 6 ; MAP kinase ; Microglia ; Monocytes ; multidisciplinary ; Neutralization Tests ; Prostaglandin E2 ; Prostaglandin-E synthase ; Prostaglandins ; Risk factors ; RNA viruses ; Science ; Science (multidisciplinary) ; Serology ; Stomatitis ; Transient receptor potential proteins ; Tumor necrosis factor-α ; Vesiculovirus - immunology ; Viral Envelope Proteins - immunology ; Viral Tropism - immunology ; Viruses</subject><ispartof>Scientific reports, 2020-08, Vol.10 (1), p.14289-14289, Article 14289</ispartof><rights>Crown 2022</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Crown 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-989eb3b6fd2a18f7bcb91f102d27bd7b2e6e952ce21f8d5320fc82c16cdbf9f83</citedby><cites>FETCH-LOGICAL-c502t-989eb3b6fd2a18f7bcb91f102d27bd7b2e6e952ce21f8d5320fc82c16cdbf9f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459353/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459353/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,41118,42187,51574,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32868837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steeds, Kimberley</creatorcontrib><creatorcontrib>Hall, Yper</creatorcontrib><creatorcontrib>Slack, Gillian S.</creatorcontrib><creatorcontrib>Longet, Stephanie</creatorcontrib><creatorcontrib>Strecker, Thomas</creatorcontrib><creatorcontrib>Fehling, Sarah Katharina</creatorcontrib><creatorcontrib>Wright, Edward</creatorcontrib><creatorcontrib>Bore, Joseph Akoi</creatorcontrib><creatorcontrib>Koundouno, Fara Raymond</creatorcontrib><creatorcontrib>Konde, Mandy Kader</creatorcontrib><creatorcontrib>Hewson, Roger</creatorcontrib><creatorcontrib>Hiscox, Julian A.</creatorcontrib><creatorcontrib>Pollakis, Georgios</creatorcontrib><creatorcontrib>Carroll, Miles W.</creatorcontrib><title>Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. Serological studies are vital to assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as alternatives to live viruses, which require high levels of bio-containment, in serological and viral entry assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseudotyped virus system, which is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics. Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could be used to provide a better understanding of the putative correlates of protection against EBOV.</description><subject>631/250</subject><subject>631/326/596</subject><subject>692/699</subject><subject>Animal models</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Brain slice preparation</subject><subject>Capsaicin</subject><subject>Capsaicin receptors</subject><subject>Capsazepine</subject><subject>Cell culture</subject><subject>Central nervous system</subject><subject>Containment</subject><subject>Cyclooxygenase-2</subject><subject>Cytokines</subject><subject>Ebola virus</subject><subject>Ebolavirus</subject><subject>Ebolavirus - immunology</subject><subject>Glycoproteins</subject><subject>Hippocampus</subject><subject>HIV</subject><subject>HIV-1 - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>MAP kinase</subject><subject>Microglia</subject><subject>Monocytes</subject><subject>multidisciplinary</subject><subject>Neutralization Tests</subject><subject>Prostaglandin E2</subject><subject>Prostaglandin-E synthase</subject><subject>Prostaglandins</subject><subject>Risk factors</subject><subject>RNA viruses</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Serology</subject><subject>Stomatitis</subject><subject>Transient receptor potential proteins</subject><subject>Tumor necrosis factor-α</subject><subject>Vesiculovirus - immunology</subject><subject>Viral Envelope Proteins - immunology</subject><subject>Viral Tropism - immunology</subject><subject>Viruses</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kVFrFDEUhQdRbKn9Az5IwBdfRpObmUzyIkiptlBQUPc1TDLJbsrsZM3NtOy_N-PWsgqalyTc7557LqeqXjL6llEu32HDWiVrCrTuGEBbsyfVKdCmrYEDPD16n1TniLe0nBZUw9Tz6oSDFFLy7rTKX9DNQ8z7XZjWJHqy-roi9yFvyKWJY0_uQpqRrMe9jbsUswsTCUhw3rkUYiI5kqvrVc2IXz4bR3pEh7h1U17EJjfn1I8BF_F-ysHEITh8UT3z_Yju_OE-q75_vPx2cVXffP50ffHhprYthVwrqZzhRvgBeiZ9Z6xRzDMKA3Rm6Aw44VQL1gHzcmg5UG8lWCbsYLzykp9V7w-6u9ls3WCLq-JG71LY9mmvYx_0n5UpbPQ63umuaRVveRF48yCQ4o_ZYdbbgNaNYz-5OKOGhisBXDS0oK__Qm_jnKayngahBO-EovA_ikkpQAGVy1g4UDZFxOT8o2VG9ZK-PqSvS_r6V_qalaZXx8s-tvzOugD8AGApTWuXjmb_W_Ynrji8Ng</recordid><startdate>20200831</startdate><enddate>20200831</enddate><creator>Steeds, Kimberley</creator><creator>Hall, Yper</creator><creator>Slack, Gillian S.</creator><creator>Longet, Stephanie</creator><creator>Strecker, Thomas</creator><creator>Fehling, Sarah Katharina</creator><creator>Wright, Edward</creator><creator>Bore, Joseph Akoi</creator><creator>Koundouno, Fara Raymond</creator><creator>Konde, Mandy Kader</creator><creator>Hewson, Roger</creator><creator>Hiscox, Julian A.</creator><creator>Pollakis, Georgios</creator><creator>Carroll, Miles W.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200831</creationdate><title>Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies</title><author>Steeds, Kimberley ; Hall, Yper ; Slack, Gillian S. ; Longet, Stephanie ; Strecker, Thomas ; Fehling, Sarah Katharina ; Wright, Edward ; Bore, Joseph Akoi ; Koundouno, Fara Raymond ; Konde, Mandy Kader ; Hewson, Roger ; Hiscox, Julian A. ; Pollakis, Georgios ; Carroll, Miles W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-989eb3b6fd2a18f7bcb91f102d27bd7b2e6e952ce21f8d5320fc82c16cdbf9f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/250</topic><topic>631/326/596</topic><topic>692/699</topic><topic>Animal models</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Brain slice preparation</topic><topic>Capsaicin</topic><topic>Capsaicin receptors</topic><topic>Capsazepine</topic><topic>Cell culture</topic><topic>Central nervous system</topic><topic>Containment</topic><topic>Cyclooxygenase-2</topic><topic>Cytokines</topic><topic>Ebola virus</topic><topic>Ebolavirus</topic><topic>Ebolavirus - immunology</topic><topic>Glycoproteins</topic><topic>Hippocampus</topic><topic>HIV</topic><topic>HIV-1 - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>MAP kinase</topic><topic>Microglia</topic><topic>Monocytes</topic><topic>multidisciplinary</topic><topic>Neutralization Tests</topic><topic>Prostaglandin E2</topic><topic>Prostaglandin-E synthase</topic><topic>Prostaglandins</topic><topic>Risk factors</topic><topic>RNA viruses</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Serology</topic><topic>Stomatitis</topic><topic>Transient receptor potential proteins</topic><topic>Tumor necrosis factor-α</topic><topic>Vesiculovirus - immunology</topic><topic>Viral Envelope Proteins - immunology</topic><topic>Viral Tropism - immunology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steeds, Kimberley</creatorcontrib><creatorcontrib>Hall, Yper</creatorcontrib><creatorcontrib>Slack, Gillian S.</creatorcontrib><creatorcontrib>Longet, Stephanie</creatorcontrib><creatorcontrib>Strecker, Thomas</creatorcontrib><creatorcontrib>Fehling, Sarah Katharina</creatorcontrib><creatorcontrib>Wright, Edward</creatorcontrib><creatorcontrib>Bore, Joseph Akoi</creatorcontrib><creatorcontrib>Koundouno, Fara Raymond</creatorcontrib><creatorcontrib>Konde, Mandy Kader</creatorcontrib><creatorcontrib>Hewson, Roger</creatorcontrib><creatorcontrib>Hiscox, Julian A.</creatorcontrib><creatorcontrib>Pollakis, Georgios</creatorcontrib><creatorcontrib>Carroll, Miles W.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steeds, Kimberley</au><au>Hall, Yper</au><au>Slack, Gillian S.</au><au>Longet, Stephanie</au><au>Strecker, Thomas</au><au>Fehling, Sarah Katharina</au><au>Wright, Edward</au><au>Bore, Joseph Akoi</au><au>Koundouno, Fara Raymond</au><au>Konde, Mandy Kader</au><au>Hewson, Roger</au><au>Hiscox, Julian A.</au><au>Pollakis, Georgios</au><au>Carroll, Miles W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-08-31</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>14289</spage><epage>14289</epage><pages>14289-14289</pages><artnum>14289</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. Serological studies are vital to assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as alternatives to live viruses, which require high levels of bio-containment, in serological and viral entry assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseudotyped virus system, which is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics. Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could be used to provide a better understanding of the putative correlates of protection against EBOV.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32868837</pmid><doi>10.1038/s41598-020-71225-1</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2020-08, Vol.10 (1), p.14289-14289, Article 14289 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7459353 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | 631/250 631/326/596 692/699 Animal models Antibodies Antibodies, Neutralizing - immunology Brain slice preparation Capsaicin Capsaicin receptors Capsazepine Cell culture Central nervous system Containment Cyclooxygenase-2 Cytokines Ebola virus Ebolavirus Ebolavirus - immunology Glycoproteins Hippocampus HIV HIV-1 - immunology Human immunodeficiency virus Humanities and Social Sciences Humans Inflammation Interleukin 6 MAP kinase Microglia Monocytes multidisciplinary Neutralization Tests Prostaglandin E2 Prostaglandin-E synthase Prostaglandins Risk factors RNA viruses Science Science (multidisciplinary) Serology Stomatitis Transient receptor potential proteins Tumor necrosis factor-α Vesiculovirus - immunology Viral Envelope Proteins - immunology Viral Tropism - immunology Viruses |
| title | Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T09%3A49%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pseudotyping%20of%20VSV%20with%20Ebola%20virus%20glycoprotein%20is%20superior%20to%20HIV-1%20for%20the%20assessment%20of%20neutralising%20antibodies&rft.jtitle=Scientific%20reports&rft.au=Steeds,%20Kimberley&rft.date=2020-08-31&rft.volume=10&rft.issue=1&rft.spage=14289&rft.epage=14289&rft.pages=14289-14289&rft.artnum=14289&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-71225-1&rft_dat=%3Cproquest_pubme%3E2696376902%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1886292083&rft_id=info:pmid/32868837&rfr_iscdi=true |